Home > Publications database > Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. > print

001     128061
005     20240228145531.0
024 7 _ |a 10.1038/bcj.2017.78
|2 doi
024 7 _ |a pmid:28841211
|2 pmid
024 7 _ |a pmc:PMC5596388
|2 pmc
024 7 _ |a altmetric:24302535
|2 altmetric
037 _ _ |a DKFZ-2017-04083
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Hillengass, Jens
|0 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5
|b 0
|e First author
245 _ _ |a Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.
260 _ _ |a London [u.a.]
|c 2017
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1510662180_10704
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis compares sensitivity and prognostic significance of WBCT and CSS in patients with smoldering MM (SMM) and MM. Fifty-four of 212 patients (25.5%) had a negative CSS and a positive WBCT for osteolytic lesions (P<0.0001). Of 66 patients with SMM based on CSS, 12 (22.2%) had osteolytic lesions on WBCT. In comparison, WBCT failed to detect some bone destructions in the appendicular skeleton possibly due to limitations of the field of view. Presence of lytic bone lesions in WBCT was of borderline prognostic significance (P=0.051) for SMM patients, with a median time to progression of 38 versus 82 months for those without bone destructions. In conclusion, WBCT identifies significantly more sites of bone destruction than CSS. More than 20% of patients with SMM according to CSS have in fact active MM detectable with WBCT. On the basis of this and other studies, WBCT (either computed tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for the detection of osteolytic lesions in MM.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Moulopoulos, L. A.
|b 1
700 1 _ |a Delorme, S.
|0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
|b 2
700 1 _ |a Koutoulidis, V.
|b 3
700 1 _ |a Mosebach, J.
|0 P:(DE-He78)9dce98b15cdeea0377ee6c204ee5373e
|b 4
700 1 _ |a Hielscher, T.
|0 0000-0003-1277-310X
|b 5
700 1 _ |a Drake, M.
|b 6
700 1 _ |a Rajkumar, S. V.
|b 7
700 1 _ |a Oestergaard, B.
|b 8
700 1 _ |a Abildgaard, N.
|b 9
700 1 _ |a Hinge, M.
|b 10
700 1 _ |a Plesner, T.
|b 11
700 1 _ |a Suehara, Y.
|b 12
700 1 _ |a Matsue, K.
|b 13
700 1 _ |a Withofs, N.
|b 14
700 1 _ |a Caers, J.
|b 15
700 1 _ |a Waage, A.
|b 16
700 1 _ |a Goldschmidt, H.
|0 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96
|b 17
|u dkfz
700 1 _ |a Dimopoulos, M. A.
|b 18
700 1 _ |a Lentzsch, S.
|b 19
700 1 _ |a Durie, B.
|b 20
700 1 _ |a Terpos, E.
|b 21
773 _ _ |a 10.1038/bcj.2017.78
|g Vol. 7, no. 8, p. e599 -
|0 PERI:(DE-600)2600560-8
|n 8
|p e599 -
|t Blood cancer journal
|v 7
|y 2017
|x 2044-5385
909 C O |o oai:inrepo02.dkfz.de:128061
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)9dce98b15cdeea0377ee6c204ee5373e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 0000-0003-1277-310X
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD CANCER J : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l Radiologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21